Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1A46 in R/R CD20+/CD19+ B-cell Non-Hodgkin's Lymphoma
NCT05987605Phase 1Terminated
- Sponsor
- BioRay Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 1A46 in B-cell non-Hodgkin lymphoma, sponsored by BioRay Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 2 more. Started Sep 2023; status: terminated.
02
Drugs
1A46
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05987605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987605.